AZN Stock Recent News
AZN LATEST HEADLINES
The FDA approves AstraZeneca's Tagrisso for treating unresectable, stage III EGFR-mutated non-small cell lung cancer.
Pfizer, Eli Lilly, AstraZeneca, Bayer and Sanofi can prove to be great additions to your portfolio.
AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of the immune system to make certain cancer drug trials more efficient, the latter said on Thursday.
AstraZeneca PLC (NASDAQ:AZN ) Deutsche Bank's Depositary Receipts Virtual Investor Conference September 24, 2024 11:30 AM ET Company Participants Elizabeth Walton - Director, Investor Relations Conference Call Participants Zafar Aziz - Deutsche Bank Hello and welcome to the Deutsche Bank Depositary Receipts of Virtual Investor Conference. My name is Zafar Aziz from the Deutsche Bank team.
British drugmaker AstraZeneca (AZN) said Monday that a Phase 3 trial of a developmental drug failed to achieve "statistical significance" in improving the length of time patients with certain types of breast cancer lived.
AstraZeneca stock slumped Monday after its Daiichi Sankyo-partnered drug missed its mark in a study of patients with breast cancer.
AstraZeneca said on Monday its experimental precision drug developed with Daiichi Sankyo did not significantly improve overall survival for patients with a type of breast cancer in a late-stage trial.
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Topline results from the TROPION-Breast01 phase 3 trial of datopotamab deruxtecan (Dato-DXd) compared to investigator's choice of chemotherapy, which previously met the dual primary endpoint of progression-free survival (PFS), did not achieve statistical significance in the final overall survival (OS) analysis in patients with inoperable or metastatic hormone receptor (HR) positive, HER2 low or negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer p.
The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's influenza nasal spray vaccine for self-administration, making it the first of its kind that patients can give themselves.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?